{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=32", "query": { "condition": "Carcinoma, Pancreas", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 2231, "total_pages": 224, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T18:58:42.862Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06549751", "title": "MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreas Cancer", "Pancreatic Cancer Metastatic", "Pancreatic Cancer (Unresectable)" ], "interventions": [ { "name": "MT-601 dose 200 million cells", "type": "DRUG" }, { "name": "MT-601 dose 400 million cells", "type": "DRUG" }, { "name": "MT-601 dose 800 million cells", "type": "DRUG" }, { "name": "MT-601 dose 1200 million cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marker Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2026-07-16", "completion_date": "2028-09-16", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06549751" }, { "nct_id": "NCT04505553", "title": "Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Carcinoma", "Colon Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Liver and Intrahepatic Bile Duct Carcinoma", "Malignant Digestive System Neoplasm", "Pancreatic Carcinoma", "Rectal Carcinoma", "Small Intestinal Carcinoma", "Anal Carcinoma", "Digestive System Carcinoma", "Digestive System Neuroendocrine Tumor", "Pancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Acupuncture Therapy", "type": "PROCEDURE" }, { "name": "Acupressure Therapy", "type": "PROCEDURE" }, { "name": "Oral Cryotherapy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2021-06-01", "completion_date": "2024-03-31", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505553" }, { "nct_id": "NCT04560712", "title": "Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Resectable Colorectal Carcinoma", "Resectable Digestive System Carcinoma", "Resectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Acupuncture Therapy", "type": "PROCEDURE" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2020-08-12", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04560712" }, { "nct_id": "NCT00903396", "title": "Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Cancer", "Carcinoma of the Appendix", "Colorectal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Gastric Cancer", "Gastrointestinal Carcinoid Tumor", "Liver Cancer", "Nausea and Vomiting", "Pancreatic Cancer", "Primary Peritoneal Cavity Cancer", "Small Intestine Cancer" ], "interventions": [ { "name": "palonosetron hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2009-09", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 69, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Moline, Illinois + 37 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Moline", "state": "Illinois" }, { "city": "Moline", "state": "Illinois" }, { "city": "Elkhart", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903396" }, { "nct_id": "NCT02826486", "title": "Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "BL-8040", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioLineRx, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2016-09", "completion_date": "2022-09-06", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • New Orleans, Louisiana + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02826486" }, { "nct_id": "NCT02548169", "title": "Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "DC Vaccine + Standard of Care Chemotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-08", "completion_date": "2017-04-24", "has_results": false, "last_update_posted_date": "2019-01-29", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02548169" }, { "nct_id": "NCT01921751", "title": "High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "low intensity radiation therapy", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "high intensity radiation therapy", "type": "RADIATION" }, { "name": "nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2018-07-13", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 46, "location_summary": "Oakland, California • Santa Clara, California • South San Francisco, California + 39 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Santa Clara", "state": "California" }, { "city": "South San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01921751" }, { "nct_id": "NCT03859869", "title": "A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Exocrine Pancreatic Insufficiency (EPI)" ], "interventions": [ { "name": "Pancrelipase", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 1, "start_date": "2020-02-25", "completion_date": "2022-03-23", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03859869" }, { "nct_id": "NCT01585805", "title": "Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2012-05-15", "completion_date": "2027-03-09", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 9, "location_summary": "Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01585805" }, { "nct_id": "NCT04809766", "title": "Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Autologous Mesothelin-specific TCR-T Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2021-12-14", "completion_date": "2025-01-15", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-19T18:58:42.862Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04809766" } ] }